Skip to main content
PMC home page
Sarcoma logoLink to Sarcoma
. 1999 Sep;3(2):79–84. doi: 10.1080/13577149977686

Susceptibility of Fibromatosis Cells in Short-Term Culture to Ifosfamide: A Possible Experimental Treatment in Clinically Aggressive Cases

Mark W Verrill 1, Helen M Coley 2, Ian R Judson 2,3, Cyril Fisher 3
PMCID: PMC2395416  PMID: 18521267

Abstract

Purpose. Deep fibromatoses are large, often rapidly growing but benign soft tissue tumours. Although surgery is the mainstay of treatment, in unremitting and aggressive cases the use of cytotoxic chemotherapy may produce objective tumour responses. Fresh tumour samples from four patients with fibromatosis were investigated as part of a study of drug resistance in soft tissue tumours.

Methods. Following short-term culture of fibromatosis cells in vitro , chemosensitivity to 4-hydroperoxy-ifosfamide, the active form of ifosfamide and doxorubicin was tested. Following 72-h continuous exposure to each drug, surviving cell fraction was assessed using the lactate dehydrogenase assay.

Results. Mean IC50 values for ifosfamide and doxorubicin were 6.2 and 0.35 µmol/l, respectively. In samples of soft tissue sarcoma (STS) from the same study the mean IC50 values for ifosfamide and doxorubicin were 14.8 and 1.69 µmol. The difference in mean ifosfamide IC50 values for fibromatosis and STS samples was statistically significant.

Discussion. We are not aware of any other report suggesting the use of ifosfamide in this condition. These observations suggest that, for patients with inoperable or progressive lesions of fibromatosis causing significant morbidity, it may be valuable to include ifosfamide in experimental treatment regimens.

Full Text

The Full Text of this article is available as a PDF (527.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauernhofer T., Stöger H., Schmid M., Smola M., Gürtl-Lackner B., Höfler G., Ranner G., Reisinger E., Samonigg H. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer. 1996 Mar 15;77(6):1061–1065. [PubMed] [Google Scholar]
  2. Brodsky J. T., Gordon M. S., Hajdu S. I., Burt M. Desmoid tumors of the chest wall. A locally recurrent problem. J Thorac Cardiovasc Surg. 1992 Oct;104(4):900–903. [PubMed] [Google Scholar]
  3. Coley H. M., Lewandowicz G., Sargent J. M., Verrill M. W. Chemosensitivity testing of fresh and continuous tumor cell cultures using lactate dehydrogenase. Anticancer Res. 1997 Jan-Feb;17(1A):231–236. [PubMed] [Google Scholar]
  4. Easter D. W., Halasz N. A. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg. 1989 Dec;210(6):765–769. doi: 10.1097/00000658-198912000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Enzinger F. M., Shiraki M. Musculo-aponeurotic fibromatosis of the shoulder girdle (extra-abdominal desmoid). Analysis of thirty cases followed up for ten or more years. Cancer. 1967 Jul;20(7):1131–1140. doi: 10.1002/1097-0142(196707)20:7<1131::aid-cncr2820200716>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  6. HUNT R. T., MORGAN H. C., ACKERMAN L. V. Principles in the management of extra-abdominal desmoids. Cancer. 1960 Jul-Aug;13:825–836. doi: 10.1002/1097-0142(196007/08)13:4<825::aid-cncr2820130427>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  7. Hamilton L., Blackstein M., Berk T., McLeod R. S., Gallinger S., Madlensky L., Cohen Z. Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases. Can J Surg. 1996 Jun;39(3):247–252. [PMC free article] [PubMed] [Google Scholar]
  8. Kiel K. D., Suit H. D. Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors). Cancer. 1984 Nov 15;54(10):2051–2055. doi: 10.1002/1097-0142(19841115)54:10<2051::aid-cncr2820541002>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  9. Kinzbrunner B., Ritter S., Domingo J., Rosenthal C. J. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer. 1983 Dec 15;52(12):2201–2204. doi: 10.1002/1097-0142(19831215)52:12<2201::aid-cncr2820521204>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  10. Kofoed H., Kamby C., Anagnostaki L. Aggressive fibromatosis. Surg Gynecol Obstet. 1985 Feb;160(2):124–127. [PubMed] [Google Scholar]
  11. Lanari A. Effect of progesterone on desmoid tumors (aggressive fibromatosis) N Engl J Med. 1983 Dec 15;309(24):1523–1523. doi: 10.1056/NEJM198312153092418. [DOI] [PubMed] [Google Scholar]
  12. Leibel S. A., Wara W. M., Hill D. R., Bovill E. G., Jr, de Lorimier A. A., Beckstead J. H., Phillips T. L. Desmoid tumors: local control and patterns of relapse following radiation therapy. Int J Radiat Oncol Biol Phys. 1983 Aug;9(8):1167–1171. doi: 10.1016/0360-3016(83)90175-x. [DOI] [PubMed] [Google Scholar]
  13. Lynch H. T., Fitzgibbons R., Jr, Chong S., Cavalieri J., Lynch J., Wallace F., Patel S. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum. 1994 Mar;37(3):260–267. doi: 10.1007/BF02048164. [DOI] [PubMed] [Google Scholar]
  14. Markhede G., Lundgren L., Bjurstam N., Berlin O., Stener B. Extra-abdominal desmoid tumors. Acta Orthop Scand. 1986 Feb;57(1):1–7. doi: 10.3109/17453678608993204. [DOI] [PubMed] [Google Scholar]
  15. McCollough W. M., Parsons J. T., van der Griend R., Enneking W. F., Heare T. Radiation therapy for aggressive fibromatosis. The Experience at the University of Florida. J Bone Joint Surg Am. 1991 Jun;73(5):717–725. [PubMed] [Google Scholar]
  16. McKinnon J. G., Neifeld J. P., Kay S., Parker G. A., Foster W. C., Lawrence W., Jr Management of desmoid tumors. Surg Gynecol Obstet. 1989 Aug;169(2):104–106. [PubMed] [Google Scholar]
  17. Patel S. R., Evans H. L., Benjamin R. S. Combination chemotherapy in adult desmoid tumors. Cancer. 1993 Dec 1;72(11):3244–3247. doi: 10.1002/1097-0142(19931201)72:11<3244::aid-cncr2820721118>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  18. Posner M. C., Shiu M. H., Newsome J. L., Hajdu S. I., Gaynor J. J., Brennan M. F. The desmoid tumor. Not a benign disease. Arch Surg. 1989 Feb;124(2):191–196. doi: 10.1001/archsurg.1989.01410020061010. [DOI] [PubMed] [Google Scholar]
  19. Raney B., Evans A., Granowetter L., Schnaufer L., Uri A., Littman P. Nonsurgical management of children with recurrent or unresectable fibromatosis. Pediatrics. 1987 Mar;79(3):394–398. [PubMed] [Google Scholar]
  20. Rock M. G., Pritchard D. J., Reiman H. M., Soule E. H., Brewster R. C. Extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1984 Dec;66(9):1369–1374. [PubMed] [Google Scholar]
  21. Waddell W. R., Gerner R. E., Reich M. P. Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol. 1983 Mar;22(3):197–211. doi: 10.1002/jso.2930220314. [DOI] [PubMed] [Google Scholar]
  22. Weiss A. J., Lackman R. D. Low-dose chemotherapy of desmoid tumors. Cancer. 1989 Sep 15;64(6):1192–1194. doi: 10.1002/1097-0142(19890915)64:6<1192::aid-cncr2820640605>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  23. Wilcken N., Tattersall M. H. Endocrine therapy for desmoid tumors. Cancer. 1991 Sep 15;68(6):1384–1388. doi: 10.1002/1097-0142(19910915)68:6<1384::aid-cncr2820680634>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES